Molecular Characterisation of Appendiceal Cancer

Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases, have had cytoreductive surgery, have availability of archival tumour tissue and have consented to our institutional biobank program or have a waiver of consent for deceased patients who have not had the opportunity to provide biobank consent (requested at the time of ethics review). Descriptive analysis of the proportion of genetic mutations identified in appendiceal cancers. This is given by the percentage of pathogenic mutations in the peritoneal metastasis compared to the primary tumour.

NCT Number	NCT05364788
Lead Sponsor	The Christie NHS Foundation Trust Collaborators: University of Manchester
Conditions	Appendiceal Cancer
Enrollment	100 participants
Start Date	2024-02-04
Primary Completion	2025-07-03 (estimated)
Study Completion	2025-07-03 (estimated)
Updated on ClinicalTrials.gov	2025-01-01